Rastogi, Priya
Tang, Gong
Hassan, Saima
Geyer, Charles E. Jr
Azar, Catherine A.
Magrinat, Gustav C.
Suga, J. Marie
Bear, Harry D.
Baez-Diaz, Luis
Sarwar, Shakir
Boileau, Jean-Francois
Brufsky, Adam M.
Shibata, Henry R.
Bandos, Hanna
Paik, Soonmyung
Yothers, Greg
Swain, Sandra M.
Mamounas, Eleftherios P.
Wolmark, Norman
Clinical trials referenced in this document:
Documents that mention this clinical trial
Association between stromal tumor-infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in patients with early breast cancer (BC) treated with neoadjuvant chemotherapy and HER2-directed therapies in NSABP B-41.
https://doi.org/10.1200/jco.2024.42.16_suppl.3017
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41
https://doi.org/10.1007/s10549-023-06881-8
Funding for this research was provided by:
GlaxoSmithKline
NSABP Foundation
Article History
Received: 30 November 2022
Accepted: 1 February 2023
First Online: 22 March 2023
Declarations
:
: The authors had full access to all the data and had final responsibility for the decision to submit for publication.
: NSABP B-41 was approved by local human investigations committees or institutional review boards in accordance with assurances filed with and approved by the US Department of Health and Human Services. Written informed consent was required.
: SH: Research funding for unrelated projects from Pfizer and Exact Sciences; Honorary Fees from Exact Sciences and Merck for Advisory Board meetings. CEG, Jr: Abbvie: Contracted Research (Terminated, Jul 1, 2022), Writing assistance (Terminated, Jul 1, 2022); AstraZeneca: Contracted Research (Ongoing), Writing assistance (Ongoing); Daiichi/Sankyo: Contracted Research (Ongoing); Exact Sciences: Consulting Fees (e.g., advisory boards) (Ongoing); F. Hoffman-La Roche Ltd: Contracted Research (Ongoing); Genentech: Contracted Research (Ongoing), Writing assistance (Ongoing) HDB: Non-relevant disclosures: Talks/honoraria, Genentech. J-FB: Honoraria/speaker’s fee: Roche, Exact Sciences, Merck, AstraZeneca; Advisory boards or speakers’ bureaus: Pfizer, Novartis, Merck. AstraZeneca, Lilly, Roche; Funded grants or clinical trials: Institutional PI, clinical trial: Roche, Merck, Lilly, Novartis, Pfizer, Bristol Myers Squibb, AstraZeneca (also Steering Committee). AMB: Consultant for AstraZeneca, Roche, Puma, Seattle Genetics, Macrogenics, Daiichi Sankyo. SMS: Grants/contracts: Genentech/Roche, Kailos Genetics, BCRF; Consulting fees: Roche/Genentech, Molecular Therapeutics; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events: Genentech/Roche, Daiichi Sankyo; Support for attending meetings and/or travel: Genentech/Roche travel to Boston 11/2019; Participation on a Data Safety Monitoring Board or Advisory Board: DSMB AstraZeneca; Ad Board: AstraZeneca, Daiichi Sankyo, Exact Sciences, Biotheranostics, Natera, Merck, Silverback Therapeutics, Athenex, Lilly; Scientific Advisory Board: Inivata. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: NSABP Vice chairman; CCF, ASCO Director; Receipt of equipment, materials, drugs, medical writing, gifts or other services: Third-party writing: Genentech/Roche and AstraZeneca. EPM: Genentech/Roche, Exact Sciences, Merck: Consultant, Speaker’s Bureau; Biotheranostics, Puma Biotechnology, Agendia, AstraZeneca: Consultant. All other authors have no other potential COIs to report.